Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2704]

Study finds chemotherapy antidote could improve recovery after chemotherapy-induced kidney toxicity

Study finds chemotherapy antidote could improve recovery after chemotherapy-induced kidney toxicity

FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection

FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection

Hair growth drug safe at low doses for breast cancer patients

Hair growth drug safe at low doses for breast cancer patients

$ASH 2024: Anitocabtagene autoleucel demonstrates 97% ORR and 62% CR/sCR in relapsed or refractory multiple myeloma$

ASH 2024: Anitocabtagene autoleucel demonstrates 97% ORR and 62% CR/sCR in relapsed or refractory multiple myeloma

ASH 2024: Belantamab mafodotin shows significant OS benefit, reducing risk of death by 42% in multiple myeloma at or after first relapse

ASH 2024: Belantamab mafodotin shows significant OS benefit, reducing risk of death by 42% in multiple myeloma at...

More cancers are being treated with personalised therapies before surgery

More cancers are being treated with personalised therapies before surgery

Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and NSCLC patients

Pharmacokinetics comparison of aumolertinib, osimertinib, gefitinib and their major metabolites in mouse model and...

Study shows how cancer cell death may harm the immune system and promote tumour growth

Study shows how cancer cell death may harm the immune system and promote tumour growth

Scientists can predict how long prostate cancer patients will respond to olaparib

Scientists can predict how long prostate cancer patients will respond to olaparib

A common heart failure medication may help prevent heart damage related to chemotherapy

A common heart failure medication may help prevent heart damage related to chemotherapy

More from ecancer